Nama's AI scorecard currently rates Intellia Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NTLA report earnings?

Intellia Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.79.

What is the NTLA price target?

The median analyst price target from 18 analysts is $16.00, with a range of $8.00 – $61.00.

Is NTLA Shariah compliant?

Nama's AAOIFI-style screen reads Intellia Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Intellia Therapeutics (NTLA)

Healthcare · Biotechnology · NASDAQ

Intellia Therapeutics (NTLA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.59B and a free-cash-flow yield of -32.2%. Over the most recent reported fiscal year, revenue grew 16.9%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -5.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-92.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.59B
Trailing P/E	—
Price / book	2.2
Price / sales	27.0
FCF yield	-32.2%
Dividend yield	—
Gross margin	0.0%
Operating margin	-1472.3%
Net margin	0.0%
Revenue growth (YoY)	+16.9%
Revenue growth (3-yr annual)	+9.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

NTLA earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.79). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.91	-$0.79	-15.2%	—
Q2 2026	Aug 6, 2026	-$0.80	-$0.78	-2.6%	$7.66M
Q1 2026	May 11, 2026	-$0.81	-$0.90	+10.0%	$15.05M
Q4 2025	Feb 26, 2026	-$0.83	-$0.96	+13.5%	$23.02M

NTLA analyst price target

Median target $16.00 from 18 analysts, ranging $8.00 – $61.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NTLA data on Nama Insights →

Recent Congressional trades

Intellia Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas R Carper	Senate	Buy	$1,001 - $15,000	—
James M Inhofe	Senate	Sell	$15,001 - $50,000	—
James M Inhofe	Senate	Buy	$15,001 - $50,000	—

NTLA FAQ

Is NTLA a buy?: Nama's AI scorecard currently rates Intellia Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NTLA report earnings?: Intellia Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.79.
What is the NTLA price target?: The median analyst price target from 18 analysts is $16.00, with a range of $8.00 – $61.00.
Is NTLA Shariah compliant?: Nama's AAOIFI-style screen reads Intellia Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.